Bristol rolls out its post-Celgene plans
(MEL EVANS/AP)
With the acquisition of Celgene on track to close later this year, Bristol-Myers Squibb is announcing big leadership and organizational changes this morning — and offering a picture of how the company plans to restructure the commercial and research operations of the combined company.
Among the many changes: Chief Scientific Officer Tom Lynch, the pioneering oncologist who joined just two years ago, will be departing. Rupert Vessey, Celgene’s president for research and early drug development, will assume that role at Bristol, reporting directly to CEO Giovanni Caforio.
The goal of the restructuring is to allow the integration of the two drug giants to proceed apace. Doing so is likely to be a massive endeavor. As of 2017, the combined companies employed 31,000 people.
Read more.
Among the many changes: Chief Scientific Officer Tom Lynch, the pioneering oncologist who joined just two years ago, will be departing. Rupert Vessey, Celgene’s president for research and early drug development, will assume that role at Bristol, reporting directly to CEO Giovanni Caforio.
The goal of the restructuring is to allow the integration of the two drug giants to proceed apace. Doing so is likely to be a massive endeavor. As of 2017, the combined companies employed 31,000 people.
Read more.
No hay comentarios:
Publicar un comentario